Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK (NCT06869122) | Clinical Trial Compass
RecruitingNot Applicable
Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK
Italy, United Kingdom18 participantsStarted 2025-07-14
Plain-language summary
This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours.
The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure.
The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Have signed informed consent.
✓. Subject is willing and able to comply with all aspects of the treatment and evaluation schedule.
✓. Are ≥ 18 years old.
✓. Have lung lesion(s)/nodule(s) which are histopathological confirmed as cancer.
✓. Have soft tissue lung lesion(s):
✓. Are candidates for surgical resection as determined by a multi-disciplinary team (MDT) or tumour board.
✓. \> 10 mm of tumour-free lung parenchyma between target tumour and pleura or fissure.
✓. Subject is willing and able to comply with the study protocol requirements.
Exclusion criteria
✕. Have target nodule(s) within the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, oesophagus, spinal cord, and phrenic \& laryngeal nerves).
What they're measuring
1
Safety of the MicroBlate Flex AB1 system in lung tumour ablation
Timeframe: Up to 21 days after the ablation procedure
2
Technical Success and Performance of the AB1 instrument